<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>26(16)</volume><submitter>Funk T</submitter><pubmed_abstract>We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).</pubmed_abstract><journal>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8063589</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.</pubmed_title><pmcid>PMC8063589</pmcid><pubmed_authors>Mossong J</pubmed_authors><pubmed_authors>Borges V</pubmed_authors><pubmed_authors>Spiteri G</pubmed_authors><pubmed_authors>O'Connor L</pubmed_authors><pubmed_authors>Suija H</pubmed_authors><pubmed_authors>Blomqvist S</pubmed_authors><pubmed_authors>Savolainen-Kopra C</pubmed_authors><pubmed_authors>Isidro J</pubmed_authors><pubmed_authors>Carr M</pubmed_authors><pubmed_authors>Pharris A</pubmed_authors><pubmed_authors>Helve O</pubmed_authors><pubmed_authors>Lo Presti A</pubmed_authors><pubmed_authors>Murphy N</pubmed_authors><pubmed_authors>Ferreira R</pubmed_authors><pubmed_authors>Garcia-Leon A</pubmed_authors><pubmed_authors>Stefanelli P</pubmed_authors><pubmed_authors>Di Martino A</pubmed_authors><pubmed_authors>Epstein J</pubmed_authors><pubmed_authors>Dotsenko L</pubmed_authors><pubmed_authors>Ikonen N</pubmed_authors><pubmed_authors>Adlhoch C</pubmed_authors><pubmed_authors>Abdelrahman T</pubmed_authors><pubmed_authors>COVID study groups</pubmed_authors><pubmed_authors>Bella A</pubmed_authors><pubmed_authors>Vergison A</pubmed_authors><pubmed_authors>Riccardo F</pubmed_authors><pubmed_authors>Gomes-Dias J</pubmed_authors><pubmed_authors>Crispie F</pubmed_authors><pubmed_authors>Gonzalez G</pubmed_authors><pubmed_authors>Wienecke-Baldacchino AK</pubmed_authors><pubmed_authors>Funk T</pubmed_authors><pubmed_authors>Casaca P</pubmed_authors><pubmed_authors>Gomes JP</pubmed_authors><pubmed_authors>Melidou A</pubmed_authors><pubmed_authors>Moreno J</pubmed_authors><pubmed_authors>Sadikova O</pubmed_authors><pubmed_authors>Mottonen T</pubmed_authors><pubmed_authors>Sepp H</pubmed_authors><pubmed_authors>Bundle N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.</name><description>We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2026-05-08T06:07:54.175Z</modification><creation>2022-02-09T16:08:04.849Z</creation></dates><accession>S-EPMC8063589</accession><cross_references><pubmed>33890566</pubmed><doi>10.2807/1560-7917.ES.2021.26.16.2100348</doi></cross_references></HashMap>